Thompson Siegel & Walmsley LLC Has $14.13 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Thompson Siegel & Walmsley LLC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 107.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 157,964 shares of the medical equipment provider’s stock after acquiring an additional 81,680 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Lantheus were worth $14,131,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of LNTH. Geode Capital Management LLC grew its position in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus during the third quarter worth $25,955,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC bought a new stake in shares of Lantheus during the fourth quarter worth $323,000. Finally, Focus Financial Network Inc. bought a new stake in shares of Lantheus during the fourth quarter worth $292,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LNTH has been the topic of several research analyst reports. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, Truist Financial increased their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $132.86.

Insider Activity

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Lantheus Trading Down 1.5 %

Shares of LNTH opened at $99.29 on Friday. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89. The stock has a market cap of $6.80 billion, a P/E ratio of 16.52 and a beta of 0.38. The stock’s 50-day moving average price is $91.66 and its two-hundred day moving average price is $96.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.